BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 28371136)

  • 1. Mitochondria-targeted antioxidant mitoquinone deactivates human and rat hepatic stellate cells and reduces portal hypertension in cirrhotic rats.
    Vilaseca M; García-Calderó H; Lafoz E; Ruart M; López-Sanjurjo CI; Murphy MP; Deulofeu R; Bosch J; Hernández-Gea V; Gracia-Sancho J; García-Pagán JC
    Liver Int; 2017 Jul; 37(7):1002-1012. PubMed ID: 28371136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitochondrial reactive oxygen species generation triggers inflammatory response and tissue injury associated with hepatic ischemia-reperfusion: therapeutic potential of mitochondrially targeted antioxidants.
    Mukhopadhyay P; Horváth B; Zsengellėr Z; Bátkai S; Cao Z; Kechrid M; Holovac E; Erdėlyi K; Tanchian G; Liaudet L; Stillman IE; Joseph J; Kalyanaraman B; Pacher P
    Free Radic Biol Med; 2012 Sep; 53(5):1123-38. PubMed ID: 22683818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antifibrotic effects of ZK14, a novel nitric oxide-donating biphenyldicarboxylate derivative, on rat HSC-T6 cells and CCl4-induced hepatic fibrosis.
    Dai L; Ji H; Kong XW; Zhang YH
    Acta Pharmacol Sin; 2010 Jan; 31(1):27-34. PubMed ID: 19966836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased hepatic platelet activating factor (PAF) and PAF receptors in carbon tetrachloride induced liver cirrhosis.
    Yang Y; Nemoto EM; Harvey SA; Subbotin VM; Gandhi CR
    Gut; 2004 Jun; 53(6):877-83. PubMed ID: 15138217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tofogliflozin Delays Portal Hypertension and Hepatic Fibrosis by Inhibiting Sinusoidal Capillarization in Cirrhotic Rats.
    Asada S; Kaji K; Nishimura N; Koizumi A; Matsuda T; Tanaka M; Yorioka N; Sato S; Kitagawa K; Namisaki T; Akahane T; Yoshiji H
    Cells; 2024 Mar; 13(6):. PubMed ID: 38534382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-proliferative and pro-apoptotic effects of tectorigenin on hepatic stellate cells.
    Wu JH; Wang YR; Huang WY; Tan RX
    World J Gastroenterol; 2010 Aug; 16(31):3911-8. PubMed ID: 20712052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carvedilol Ameliorates Intrahepatic Angiogenesis, Sinusoidal Remodeling and Portal Pressure in Cirrhotic Rats.
    Ling L; Li G; Meng D; Wang S; Zhang C
    Med Sci Monit; 2018 Nov; 24():8290-8297. PubMed ID: 30448852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The mitochondria-targeted antioxidant MitoQ ameliorates inorganic arsenic-induced DCs/Th1/Th2/Th17/Treg differentiation partially by activating PINK1-mediated mitophagy in murine liver.
    Li H; Guo Y; Su W; Zhang H; Wei X; Ma X; Gong S; Qu G; Zhang L; Xu H; Shen F; Jiang S; Xu D; Li J
    Ecotoxicol Environ Saf; 2024 Jun; 277():116350. PubMed ID: 38653026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Redox-crippled MitoQ potently inhibits breast cancer and glioma cell proliferation: A negative control for verifying the antioxidant mechanism of MitoQ in cancer and other oxidative pathologies.
    Cheng G; Karoui H; Hardy M; Kalyanaraman B
    Free Radic Biol Med; 2023 Aug; 205():175-187. PubMed ID: 37321281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mitochondrial dysfunction using methylene blue or mitoquinone to improve skeletal aging.
    Poudel SB; Frikha-Benayed D; Ruff RR; Yildirim G; Dixit M; Korstanje R; Robinson L; Miller RA; Harrison DE; Strong JR; Schaffler MB; Yakar S
    Aging (Albany NY); 2024 Mar; 16(6):4948-4964. PubMed ID: 38535998
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitochondrial respiratory function and antioxidant capacity in normal and cirrhotic livers following partial hepatectomy.
    Yang S; Tan TM; Wee A; Leow CK
    Cell Mol Life Sci; 2004 Jan; 61(2):220-9. PubMed ID: 14745500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The mechanical mechanism of angiotensin II induced activation of hepatic stellate cells promoting portal hypertension.
    Zhang Y; Xing M; Meng F; Zhu L; Huang Q; Ma T; Fang H; Gu X; Huang S; Wu X; Lv G; Guo J; Wu L; Liu X; Chen Z
    Eur J Cell Biol; 2024 May; 103(2):151427. PubMed ID: 38820882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Involvement of vasoactive substances in hemodynamics disturbances in cirrhosis.
    Grancea-Iancu M
    J Med Life; 2014; 7 Spec No. 3(Spec Iss 3):40-3. PubMed ID: 25870693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The genetics of portal hypertension: Recent developments and the road ahead.
    Shalaby S; Ronzoni L; Hernandez-Gea V; Valenti L
    Liver Int; 2023 Dec; 43(12):2592-2603. PubMed ID: 37718732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic prehepatic portal hypertension in the rat: is it a type of metabolic inflammatory syndrome?
    Sánchez-Patán F; Anchuelo R; Aller MA; Vara E; García C; Nava MP; Arias J
    Lipids Health Dis; 2008 Feb; 7():4. PubMed ID: 18271959
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral subchronic toxicity study and genetic toxicity evaluation of mitoquinone mesylate.
    Mitchell ES; Lemke S; Woodhead B; Coleman D
    J Appl Toxicol; 2024 Jun; ():. PubMed ID: 38860421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A novel modular bioreactor to in vitro study the hepatic sinusoid.
    Illa X; Vila S; Yeste J; Peralta C; Gracia-Sancho J; Villa R
    PLoS One; 2014; 9(11):e111864. PubMed ID: 25375141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SH-Alb inhibits phenotype remodeling of pro-fibrotic macrophage to attenuate liver fibrosis through SIRT3-SOD2 axis.
    Wu N; Ma S; Ding H; Cao H; Liu T; Tian M; Liu Q; Bian H; Yu Z; Liu C; Wang L; Feng Y; Wu H; Qi J
    Biomed Pharmacother; 2024 Jun; 176():116919. PubMed ID: 38876053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interspecies transcriptomic comparison identifies a potential porto-sinusoidal vascular disorder rat model suitable for in vivo drug testing.
    Campreciós G; Vilaseca M; Tripathi DM; Montironi C; Díaz A; Aguilar D; García-Calderó H; Montañés R; Anton A; Hernández-Gea V; García-Pagán JC
    Liver Int; 2024 Jan; 44(1):180-190. PubMed ID: 37872644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanodrug with ROS and pH Dual-Sensitivity Ameliorates Liver Fibrosis via Multicellular Regulation.
    Lin L; Gong H; Li R; Huang J; Cai M; Lan T; Huang W; Guo Y; Zhou Z; An Y; Chen Z; Liang L; Wang Y; Shuai X; Zhu K
    Adv Sci (Weinh); 2020 Apr; 7(7):1903138. PubMed ID: 32274310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.